2m 2m 2m 2m 2m 2m 2m
- $689.8MMarket Cap
- -1.68%1-Year Change
- Medical DevicesIndustry
CERIBELL (CBLL)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 50
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
Ceribell obtained FDA 510(k) clearance for its ClarityⓇ algorithm, becoming the first AI-powered point-of-care EEG technology capable of detecting electrographic seizures across all patient ages, from pre-term neonates to adults.
11/24/2025, 8:00 AM • GlobeNewswire
Medtech Leader Erica Rogers Joins Ceribell Board of Directors
Medical technology company Ceribell announced the appointment of Erica Rogers to its Board of Directors, bringing over three decades of healthcare leadership experience to help expand nationwide access to their point-of-care EEG system.
09/22/2025, 8:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
Key Executives
- Xingjuan Chao
- Scott Blumberg
- Raymond Woo
- Josef Parvizi
- Louisa Daniels
Current Ownership Distribution
- Institutions151.1M (94.06%)
- Mutual Funds8.1M (5.04%)
- Insiders1.4M (0.90%)
- Other0 (0.00%)